HC Wainwright Has Lowered Expectations for Sana Biotechnology (NASDAQ:SANA) Stock Price

Sana Biotechnology (NASDAQ:SANA) had its target price cut by analysts at HC Wainwright from $9.00 to $7.00 in a research report issued on Wednesday, Marketbeat reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 105.28% from the company’s previous close. HC Wainwright also issued estimates for Sana Biotechnology’s FY2030 earnings at ($0.49) EPS.

A number of other equities analysts also recently issued reports on SANA. Zacks Research upgraded Sana Biotechnology from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. Wedbush increased their price target on shares of Sana Biotechnology from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Bank of America boosted their price objective on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Wall Street Zen downgraded shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Monday, December 29th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.83.

Sana Biotechnology Price Performance

Shares of SANA opened at $3.41 on Wednesday. The company has a 50-day simple moving average of $4.27 and a two-hundred day simple moving average of $4.14. The firm has a market capitalization of $910.03 million, a PE ratio of -3.52 and a beta of 1.96. Sana Biotechnology has a one year low of $1.26 and a one year high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). Analysts expect that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Sana Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the company. Marex Group plc purchased a new position in Sana Biotechnology in the 2nd quarter worth approximately $10,423,000. Balyasny Asset Management L.P. bought a new stake in shares of Sana Biotechnology in the 4th quarter worth $6,834,000. Vanguard Group Inc. raised its stake in shares of Sana Biotechnology by 19.9% in the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after purchasing an additional 1,517,474 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Sana Biotechnology by 180.8% during the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after purchasing an additional 1,375,029 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Sana Biotechnology by 20.6% during the fourth quarter. State Street Corp now owns 8,054,841 shares of the company’s stock valued at $32,783,000 after buying an additional 1,374,300 shares during the last quarter. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.